Ref ID: 18704
Author:
M. A. Pfaller, MD – Cons 1, S. A. Messer, MS – MT 1, M. R. Motyl, PhD – Lead Sci 2, R. N. Jones, MD – CEO 1, M. Castanheira, PhD – Dir1;
Author address:
1JMI Lab., N Liberty, IA, 2Merck Sharp & Dohme Corp, Kenilworth, NJ.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: MK-3118 is a potent inhibitor of fungal glucan synthase that is derived from enfumafungin. We compared the activity of MK-3118 against Aspergillus spp. (ASP) and Candida spp. (CSP) using CLSI and EUCAST (BMD) methods.
Methods: 71 ASP (23 A. flavus [AFL], 21 A. fumigatus [AFU], 9 A. niger [ANG], and 18 A. terreus [ATR]) and 113 CSP (29 C. albicans [CA], 29 C. glabrata [CGLA], 15 C. parapsilosis [CPRP], 21 C. tropicalis [CTRO] and 18 C. krusei [CKRU]) were tested against MK-3118, amphotericin B (AMB; ASP) and fluconazole (FLC; CSP) and caspofungin (CAS) by CLSI and EUCAST methods. MK-3118 was read at 24-h, 48-h, 50% and 100% inhibition. ASP included 8 itraconazole (ITR)-resistant (R; MIC, ≥ 4 µg/ml) and CSP included 31 CAS-R fks hot spot (HS) mutants (16 also FLC-R) and 19 FLC-R.
Results: Activities of MK-3118, CAS, FLC and AMB are displayed in the Table. MK-3118 demonstrated good activity against ASP and CSP. MK-3118 showed excellent activity against ITR-R strains of AFU (MEC range, 0.03 to 0.5 µg/ml), ANG and ATR (MEC, 0.06 and 0.12 µg/ml, respectively). MK-3118 was very active against FLC-R CA (MIC range, 0.06-2 µg/ml), CGLA (0.5-2 µg/ml), CTRO (0.25-1 µg/ml), and CPRP (0.25-0.5 µg/ml) and was most potent against CAS-R CA (MIC range, 0.12-2 µg/ml), CGLA (0.5-2 µg/ml), CTRO (0.25-2 µg/ml) and CKRU (0.5-2 µg/ml). Overall essential agreement (±2 log2 dilution steps) was 94.3% for ASP and 97.1% for CSP.
Conclusions: MK-3118 was shown to be a potent and broad-spectrum antifungal agent regardless of the BMD method applied, with excellent activity against challenging R strains of ASP and CSP.
Abstract Number: M-1714
Conference Poster: y
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a